Xiamen AmonMed Biotechnology Co., Ltd., was established in 2014, focusing on the in-depth research of the global scarce strategic resource "rare earth" and its high-value application in the research, development and production of in vitro diagnostic products and instruments. The products have been sold to more than 20 countries around the world and domestic provinces and cities.  

As a pioneer of rare earth biomedical enterprises in China, AmonMed has strong scientific research strength and has undertaken a number of national and provincial projects.  At present AmonMed has 13 patents of rare earth in the field of biomedical, and successfully developed a series of exclusive worldwide and has independent intellectual property rights of the rare earth nanometer fluorescence immunity in vitro diagnostic products, among them 35 products through the CE certification, 25 items in vitro diagnostic reagents and two rare earth nanometer fluorescence immunoassay analyzer got national medical device registration certificate,  It includes novel coronavirus test, myocardial triple test, C-reactive protein test, D-dimer test and other reagents.